(DTIL), Eli Lilly and Company (NYSE:LLY) - Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows
Precision BioSciences Inc (NASDAQ: DTIL) has announced three-year follow-up data showing long-term stable reduction of low-density ...
Source: benzinga.com